David Meyer, PhD “Welcome Remarks & Introduction to LA BioMed”
•
2 likes•642 views
David Meyer, PhD “Welcome Remarks & Introduction to LA BioMed” President/CEO, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center
![Statistics:
• Independent/Not-for-profit [501(c)(3)]
• 650-1000 research projects
• ~100 Investigators - MDs & PhDs
– 75% are LA County Employees
(Harbor-UCLA)
• 950+ employees (700 on campus)](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
More Related Content
Viewers also liked
Viewers also liked (7)
Similar to David Meyer, PhD “Welcome Remarks & Introduction to LA BioMed”
Similar to David Meyer, PhD “Welcome Remarks & Introduction to LA BioMed” (20)
More from UCLA CTSI
More from UCLA CTSI (20)
Recently uploaded
Recently uploaded (20)
David Meyer, PhD “Welcome Remarks & Introduction to LA BioMed”
- 2. Statistics: • Independent/Not-for-profit [501(c)(3)] • 650-1000 research projects • ~100 Investigators - MDs & PhDs – 75% are LA County Employees (Harbor-UCLA) • 950+ employees (700 on campus)
- 3. Missions: Biomedical Research Training and Education Community Service
- 4. Relationships Academic Medical Center Clinical Care Teaching Research
- 5. Relationships Harbor-UCLA Clinical Care Medical Center UCLA Teaching School of Medicine LA BioMed Research
- 6. LA BioMed Paradigm What we see in the clinic is what we study in the lab. Our discoveries are rapidly and efficiently protected and developed commercially By doing so, LA BioMed IP arrives in the clinic in less time.
- 7. LA BioMed Highlights 1960’s-Present Paramedic Training Program Nurse-Practitioner Training Program Serum Cholesterol Test Tay-Sachs Blood Test 170,00 Live Births through Ovum Transfer Synthetic Lung Surfactants Anti-microbial eye drops COPD Rehab Therapy Vaccines against Hospital-acquired Infections Treatment for Sickle Cell Disease Male Birth Control Gel Melanoma Vaccine
- 8. On the Cutting Edge…
- 9. Licensing of LA BioMed IP 2001 2004 2005 2007 2011: PulSentry ImmunoTx 2012: BioAIM SyneuRx
- 10. Submental Fat
- 11. Treatment For Submental Fat Michael Kolodney Now in Phase III Clinical Trials IPO October 2012
- 12. Sickle Cell Disease Red Blood Cells
- 13. Novel Inexpensive Therapy for Sickle Cell Disease Yutaka Niihara In Phase III Clinical Trials
- 14. Nosocomial = Hospital Acquired Infections 6th Leading Cause of Death Candida albicans 60% Lethality 1. More invasive procedures 2. Antibiotic Resistance 3. No ROI Staphylococcus aureus
- 15. Vaccines against Nosocomial Infections Jack Edwards Phase II Clinical Trials Starting Soon
- 17. LA BioMed Paradigm What we see in the clinic is what we study in the lab. Our discoveries are rapidly and efficiently protected and developed commercially By doing so, LA BioMed IP arrives in the clinic in less time.